Latest Developments in Tricuspid Regurgitation

The natural history of tricuspid regurgitation is associated to hospitalization for cardiac failure and mortality. This is why the AHA/ACC guidelines recommend surgery when the tricuspid fails during left valve surgical repair, because its slow progression is associated with high mortality (35%).

Avances en el tratamiento de la insuficiencia tricuspídea

Many of these patients are high risk and percutaneous intervention has surged as an interesting alternative, even though at present its inhospital complication rates range from 5% to 9%, depending on the series.

The study analyzed the CLASP TR at one year, which included 65 patients with tricuspid regurgitation. The PASCAL and PASCAL ACE were used.

Patient mean age was 77, more than half were women, 15% presented diabetes, 30% heart disease, 6% MI, 10% stroke, 28% ascites, 9% cirrhosis, and 7% intestinal bleeding. 

43% had kidney function deterioration and eGFR was 53 ml/min. 

30% presented myocardial revascularization surgery (CABG), 16% aortic valve surgery or intervention, and 20% mitral valve surgery or intervention. Also, 14% had a pacemaker. 

Read also: Drug Coated Balloons: Link between Femoropopliteal Lesion Calcification Grade and Clinical Outcomes.

All patients were in functional class (FC) III-IV and mortality STS score was 5%.

97% presented severe tricuspid regurgitation, massive or torrential. 

Implantation success rate was 90.8%, and most patients received between one and two devices. 

At 30 days, mortality resulted 3.1%, stroke 1.5% and there were no differences in need for reintervention.

Read also: Is IVUS Useful in Lower Limb PCI?

Between 30 days and one year, 3 patients presented cardiovascular death, 2 stroke, and one reintervention. 

At one year, survival was 87.9% and freedom from hospitalization for cardiac failure was 78%. 92% were in functional class I-II, 86% had mild to moderate tricuspid regurgitation with significant improvement in quality of like, and 6-minute walk test. ECG showed significant reduction of tricuspid annulus diameter, regurgitation jet, right ventricular end-diastolic diameter, right atrial diameter and volume and vena cava diameter. 

The annualized reduction by hospitalization for cardiac failure pre and post implantation was 56%.

Conclusion

The PASCAL system showed low complications and high survival rates with sustained improvement in tricuspid regurgitation, functional capacity and quality of life at one year. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: 1-Year Outcomes of Transcatheter Tricuspid Valve Repair.

Reference: Kodali, et al. J Am Coll Cardiol 2023;81:1766–1776.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...